Relative to traditional chemotherapy, EGFR-TKI therapy significantly extended progression-free survival (PFS), overall survival (OS), and improved quality of life due to relatively low toxicity for NSCLC patients harboring sensitive EGFR mutations [9,10,11,12,13,14,15,16,17,18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.